Jefferies Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $275
Express News | ICON Plc Released The Findings Of A Survey Of Over 120 Biotech And Pharma Professionals Developing Treatments For Neurodegenerative Disorders
Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer's and Related Disorders ICON Survey
ICON Plc Draws Bullish Views at RBC on Attractive Valuation
Express News | Icon Shares Are Trading Higher After RBC Capital Initiated Coverage on the Stock With an Outperform Rating and Announced a Price Target of $263
ICON Up Over 5%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk
ICON Public Limited Company (NASDAQ:ICLR) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
